• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

    7/8/25 9:00:00 AM ET
    $LH
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $LH alert in real time by email

    ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors.

    "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as we continue to grow our business and build scaled provider networks across the U.S."

    Mr. Berberian is a technology strategist with over 30 years of experience specializing in digital transformation and corporate governance. From 2014 to October 2024, he served as EVP and Chief Information and Technology Officer at Labcorp Holdings Inc. (NYSE:LH), overseeing a team of 5,000 people focused on IT strategy, cybersecurity, AI, product development, and data management. Prior to Labcorp, Mr. Berberian held CIO roles at IDEXX Laboratories, Kellstrom Aerospace, Interim HealthCare and Quest Diagnostics.

    Mr. Berberian currently serves on the Elon University Board of Trustees and previously chaired the NC State Computer Science Strategic Advisory Board. He holds a bachelor's degree in business administration and information technology from Thomas Edison State College.

    About Privia Health

    Privia Health™ is one of the largest physician enablement companies in the United States with a presence in 15 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,200+ physician practices, improve the patient experience for 5.2+ million patients, and reward 4,800+ physicians and advanced practitioners for delivering high-value care.

    Privia's mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit priviahealth.com and connect with us on LinkedIn.

    Safe Harbor Statement

    This release may contain forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in filings with the Securities and Exchange Commission ("SEC"), including those under "Risk Factors" therein. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date made. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

    Contact:

    Robert Borchert

    SVP, Investor & Corporate Communications

    [email protected]         

    817.783.4841



    Primary Logo

    Get the next $LH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LH
    $PRVA

    CompanyDatePrice TargetRatingAnalyst
    Labcorp Holdings Inc.
    $LH
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    Labcorp Holdings Inc.
    $LH
    4/2/2025$276.00Buy
    Redburn Atlantic
    Labcorp Holdings Inc.
    $LH
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    Privia Health Group Inc.
    $PRVA
    1/10/2025$25.00Buy
    Needham
    Labcorp Holdings Inc.
    $LH
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    Privia Health Group Inc.
    $PRVA
    12/16/2024Outperform
    Macquarie
    Labcorp Holdings Inc.
    $LH
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    Labcorp Holdings Inc.
    $LH
    10/30/2024Hold → Buy
    HSBC Securities
    More analyst ratings

    $LH
    $PRVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Pres, Central Labs & Intl Bailey Megan D. converted options into 370 shares and covered exercise/tax liability with 179 shares, increasing direct ownership by 6% to 3,594 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    11/4/25 1:43:28 PM ET
    $LH
    Medical Specialities
    Health Care

    EVP, CIO & CTO Oyegunwa Akinbolade converted options into 370 shares and covered exercise/tax liability with 107 shares, increasing direct ownership by 8% to 3,727 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    11/4/25 1:35:33 PM ET
    $LH
    Medical Specialities
    Health Care

    Director Parham Richelle P sold $1,782,273 worth of shares (7,009 units at $254.28), decreasing direct ownership by 74% to 2,469 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    11/4/25 10:28:19 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    $PRVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Boehler Adam bought $6,006 worth of shares (364 units at $16.50) (SEC Form 4)

    4 - Privia Health Group, Inc. (0001759655) (Issuer)

    6/13/24 4:05:22 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Boehler Adam bought $87,549 worth of shares (5,306 units at $16.50) (SEC Form 4)

    4 - Privia Health Group, Inc. (0001759655) (Issuer)

    5/31/24 4:13:08 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Boehler Adam bought $70,577 worth of shares (4,280 units at $16.49) (SEC Form 4)

    4 - Privia Health Group, Inc. (0001759655) (Issuer)

    5/29/24 4:08:14 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    $LH
    $PRVA
    SEC Filings

    View All

    SEC Form S-3ASR filed by Privia Health Group Inc.

    S-3ASR - Privia Health Group, Inc. (0001759655) (Filer)

    11/6/25 4:14:27 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by Privia Health Group Inc.

    10-Q - Privia Health Group, Inc. (0001759655) (Filer)

    11/6/25 8:45:50 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Privia Health Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Privia Health Group, Inc. (0001759655) (Filer)

    11/6/25 6:09:22 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    $LH
    $PRVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Privia Health Reports Third Quarter 2025 Financial Results

    Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1% compared to 3Q'24FY'25 Guidance Raised Above High End for All Key Operating and Financial Metrics ARLINGTON, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) today announced financial results for the third quarter ended September 30, 2025. Third Quarter Performance   For the Three Months Ended September 30,  ($ in millions, except per share amounts)  2025  2024 Change (%) fTotal revenue $580.4 $437.9 32.5%Gross profit $122.6 $99.9 22.7%Operating income $14.4 $5.8 1

    11/6/25 6:00:00 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Labcorp Announces 2025 Third Quarter Results

    Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024:Revenue: $3.56 billion versus $3.28 billionDiluted EPS: $3.12 versus $2.00Adjusted EPS: $4.18 versus $3.50Updated Full-Year Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue guidance of 7.4% to 8.0%; midpoint lowered 40 bps due to currency and acquisition timingAdjusted EPS range of $16.15 to $16.50; midpoint raised by $0.05Free Cash Flow range of $1.17 billion to $1.29 billion; midpoint raised by $25 millionSigned several strategic agreements with health systems and regional/local laboratoriesAdvanced business in high-growth specialty testing areas, including onco

    10/28/25 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings

    Labcorp plans to make Roche's Elecsys® pTau181 test available nationwide by early 2026 BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting. Developed by Roche Diagnostics, Labcorp plans to make the test available nationwide by early 2026. An est

    10/23/25 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    $PRVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

    7/10/25 9:03:30 AM ET
    $LH
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

    Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

    4/2/25 8:50:29 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. upgraded by Citigroup with a new price target

    Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

    3/4/25 7:36:42 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    $PRVA
    Financials

    Live finance-specific insights

    View All

    Privia Health Reports Third Quarter 2025 Financial Results

    Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1% compared to 3Q'24FY'25 Guidance Raised Above High End for All Key Operating and Financial Metrics ARLINGTON, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) today announced financial results for the third quarter ended September 30, 2025. Third Quarter Performance   For the Three Months Ended September 30,  ($ in millions, except per share amounts)  2025  2024 Change (%) fTotal revenue $580.4 $437.9 32.5%Gross profit $122.6 $99.9 22.7%Operating income $14.4 $5.8 1

    11/6/25 6:00:00 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Labcorp Announces 2025 Third Quarter Results

    Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024:Revenue: $3.56 billion versus $3.28 billionDiluted EPS: $3.12 versus $2.00Adjusted EPS: $4.18 versus $3.50Updated Full-Year Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue guidance of 7.4% to 8.0%; midpoint lowered 40 bps due to currency and acquisition timingAdjusted EPS range of $16.15 to $16.50; midpoint raised by $0.05Free Cash Flow range of $1.17 billion to $1.29 billion; midpoint raised by $25 millionSigned several strategic agreements with health systems and regional/local laboratoriesAdvanced business in high-growth specialty testing areas, including onco

    10/28/25 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Declares Quarterly Dividend

    BURLINGTON, N.C., Oct. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 11, 2025, to stockholders of record as of the close of business on November 26, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and

    10/8/25 4:15:00 PM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    $PRVA
    Leadership Updates

    Live Leadership Updates

    View All

    Privia Health Expands Value-Based Care Footprint with Acquisition of Accountable Care Organization Business from Evolent Health

    ARLINGTON, Va., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced that it signed a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE:EVH). The ACO business cares for over 120,000 attributed lives through the Medicare Shared Savings Program (MSSP), as well as various commercial and Medicare Advantage programs. With this transaction, Privia Health will now serve approximately 1.5 million attributed lives in value-based care (VBC) arrangements across commercial, Medicare, Medicare Advantage and Medicaid. Privia Health will pay $100 million in cash at closing and up to an additional $13 million su

    9/23/25 4:10:00 PM ET
    $EVH
    $PRVA
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

    ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as

    7/8/25 9:00:00 AM ET
    $LH
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services

    SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

    SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv

    5/12/25 9:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    $PRVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Privia Health Group Inc.

    SC 13G/A - Privia Health Group, Inc. (0001759655) (Subject)

    11/14/24 5:20:21 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Privia Health Group Inc.

    SC 13G/A - Privia Health Group, Inc. (0001759655) (Subject)

    11/12/24 10:34:17 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Privia Health Group Inc.

    SC 13G/A - Privia Health Group, Inc. (0001759655) (Subject)

    7/10/24 1:14:41 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care